Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study

Current Hypertension Reports

Volumn 6, Issue 2, 2004, Pages 106-110

  Punzi, Henry A ^a   Punzi, Connie F ^a  

^a Punzi Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; LISINOPRIL; LOSARTAN; PROPRANOLOL; RESERPINE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL; BENZOTHIADIAZINE DERIVATIVE; DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG COST; DRUG MECHANISM; FATALITY; GLUCOSE INTOLERANCE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INCIDENCE; INSULIN RELEASE; METABOLIC PARAMETERS; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; HYPERLIPIDEMIA; REVIEW;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BENZOTHIADIAZINES; CLINICAL TRIALS; DIABETES MELLITUS; DIURETICS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MYOCARDIAL INFARCTION; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 4644299727     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0084-7     Document Type: Article

References (28)

1. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
2. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 35: 65-774.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitors or calcium channel blockers vs. diuretics. JAMA 2002, 288: 981-2997.
4. Davis BR, Cutler JA, Gordon DJ, et al.: Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 1996, 9:342-360.
5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967-1975.
6. Messerli FH: ALLHAT, or the soft science of the secondary end point. Ann Intern Med 2003, 139:777-780.
7. Wilkins RW: New drugs for the treatment of hypertension. Ann Intern Med 1959, 5:1-10.
8. Freis ED, Wanko A, Wilson IM, et al.: Treatment of hypertension with chlorothiazide (Diuril). JAMA 1958, 166: 37-140.
9. Hermansen K, Schmitz O, Arnfred J, et al.: Effects of furosemide and indapamide upon pancreatic insulin and somatostatin secretion in vivo. Diabetes Res 1986, 3:221-223.
10. Helderman JH, Elahi D, Andersen GS, et al.: Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983, 32:106-111.
11. Ames RP, Hill P: Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuation of antihypertensive drug therapy. Circulation 1982, 65:899-904.
12. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321: 68-873.
13. Ferrannini E, Buzziogli G, Bonadonna R, et al.: Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
14. Janssen I, Katzmarzyk PT, Ross R: Body mass index, waist circumference, and health risk. Arch Intern Med 2002, 162: 074-2079.
15. Neutel JM, Smith DHG: Hypertension control: multilactorial contributions. Am J Hypertens 1999, 12:1645-1695.
16. Younis N, Broadbent DM, Vora JP, Harding SP: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003, 361:195-200.
17. Henry P, Thomas F, Benetos A, et al.: Impaired fasting glucose, blood pressure and cardiovascular mortality. Hypertension 2002, 40:458-463.
18. Wassertheil-Smoller S, Oberman A, Blaufox MD, et al.: The trial of antihypertensive interventions and management (TAIM) study: final results with regards to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992, 5:37-44.
19. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002, 288:2579-2588.
20. Watkins LL, Sherwood A, Feinglos M, et al.: Effects of exercise and weight loss on cardiac risk factors associated with syndrome X. Arch Intern Med 2003, 163:1889-1895.
21. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
22. Lewis PJ, Kohner EM, Petrie A, et al.: Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic therapy. Lancet 1976, 1:546-566.
23. Totterman K, Groop L, Groop P-H, et al.: Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. Eur J Clin Pharm 1984, 26:13-17.
24. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995-2003.
25. Pepine C, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
26. Cleeman J: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001, 285:2486-2496.
27. Punzi HA: Hypertension and concomitant diseases. In Clinical Cardiovascular Therapeutics. Edited by Punzi HA, Flamenbaum W. Mt Kisco, NY: Futura Publishing; 1989:247-266.
28. Punzi HA: Hypertension and concomitant diseases. In Clinical Cardiovascular Therapeutics: Hypertension, Vol 1. Edited by Punzi HA, Flamenbaum W. Mount Kisco, NY: Futura; 1989:395-398.